# Avoiding Growth Factor During Paclitaxel Treatment in Breast Cancer

> **NCT02698891** · PHASE2 · COMPLETED · sponsor: **Dana-Farber Cancer Institute** · enrollment: 127 (actual)

## Conditions studied

- Early Stage Breast Cancer

## Interventions

- **DRUG:** Paclitaxel
- **DRUG:** Neulasta

## Key facts

- **NCT ID:** NCT02698891
- **Lead sponsor:** Dana-Farber Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-04-07
- **Primary completion:** 2020-12
- **Final completion:** 2021-11
- **Target enrollment:** 127 (ACTUAL)
- **Last updated:** 2022-05-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02698891

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02698891, "Avoiding Growth Factor During Paclitaxel Treatment in Breast Cancer". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT02698891. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*